Remove Clinical Trials Remove Data Remove Media Remove Patients
article thumbnail

Cannabis 3.0 Accelerates Access to Consumer and Medical Research

Cannabis Law Report

A Windsor, Ontario-based company Audacia Bioscience is especially focussed on three patented technologies that deliver consumer and patient insights to the industry to close the knowledge gaps in the supply chain. Virtual Clinical Trials transcend geographic, mobility and economic barriers.

article thumbnail

MyMD Pharmaceuticals Announces New Data from Comparative Study on Lead Compound MYMD-1

Cannabis Law Report

New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. Company plans to initiate Phase II trial with a leading academic institution. Current TNF-a inhibitors available today, while effective, come with an array of adverse effects and concerns for patients,” said Adam Kaplin, M.D.,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Press Release: COMPASS Pathways plc financial results second quarter 2021 – Reminds us of that rich people’s festival in the desert

Cannabis Law Report

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. Guy Goodwin appointed Chief Medical Officer and Danielle Schlosser appointed Senior Vice-President, Clinical Innovation. On track to report top-line data by end of 2021.

article thumbnail

Compass Pathways granted fifth US patent for crystalline psilocybin

Cannabis Law Report

London, UK – 23 November 2021 COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted its fifth patent by the US Patent and Trademark Office. PRESS RELEASE. ” About COMPASS Pathways.

article thumbnail

MedXtractor Fills a Key Gap in Mental Health Treatments

Cannabis Law Report

In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials. Despite the high prevalence of these disorders, few patients are accurately screened and diagnosed. Building the Data Backend.

article thumbnail

Goldfinch Bio Announces Upcoming Presentations at American Society of Human Genetics (ASHG) 2021 Meeting and American Society of Nephrology’s (ASN) Kidney Week 2021

Cannabis Law Report

The presentation details the identification of a novel locus on chromosome 14 which is associated with proteinuric kidney disease and includes data which confirms the well-known association of APOL1 risk haplotypes (i.e., DNA variations or polymorphisms) in patients with African ancestry. Poster Number: INFO37.

article thumbnail

DEA Approves MMJ International Holdings THC Shipment for Multiple Sclerosis, Huntington’s Disease Drug Development

Cannabis Law Report

. “As MMJ International Holdings continues to advance to its clinical trials, a specialty pharmaceutical solutions company will be supporting MMJ with the FDA, DEA required development API and specialized liquid encapsulation solutions,” said Elio Mariani, PhD, EVP of Research & Development. 561-627-9455. 917-562-9610.

DEA 66